Phase 2, multicenter, randomized clinical study to evaluate the efficacy and safety of safusidenib in patients with high-grade isocitrate dehydrogenase 1 (IDH1)-mutant glioma

Phase 2, multicenter, randomized clinical study to evaluate the efficacy and safety of safusidenib in patients with high-grade isocitrate dehydrogenase 1 (IDH1)-mutant glioma Read More »